Helena Marzo‐Ortega
YOU?
Author Swipe
View article: OA05 The many faces of treatment-refractory spondyloarthritis
OA05 The many faces of treatment-refractory spondyloarthritis Open
Introduction Spondyloarthritis is a group of inflammatory diseases sharing diverse genetic and clinical features, chiefly inflammation of peripheral or axial joints and entheses. Tissue involvement outside the musculoskeletal systems is ty…
View article: P015 This one ‘struck a cord’: when clinical history matters more than the MRI
P015 This one ‘struck a cord’: when clinical history matters more than the MRI Open
Introduction Transverse myelitis (TM) is a rare inflammatory condition of the spinal cord with multiple potential triggers, including infections, autoimmune disorders, and, rarely, vaccinations. Post-vaccination TM has been primarily assoc…
View article: Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis
Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis Open
View article: EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis
EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis Open
EULAR proposes 2 consensus definitions to identify a D2M PsA population, including a TR subgroup. These definitions should now be tested in research studies to understand disease pathogenesis and improve care for people living with PsA.
View article: Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies Open
Objective To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3…
View article: Utility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres
Utility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres Open
Introduction The role of MRI of the spine/sacroiliac joints to aid the diagnosis of axial spondyloarthritis (axSpA) is well established. Limited data, however, exist on the use of MRI to assess disease activity, resulting in current Assess…
View article: Current understanding of the challenges in the diagnosis and management of spondyloarthritis in older adults
Current understanding of the challenges in the diagnosis and management of spondyloarthritis in older adults Open
Spondyloarthritis (SpA) encompasses a group of immune-mediated, inflammatory diseases, most notably axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). As the global population ages, so does the population living with these cond…
View article: Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS <i>post hoc</i> analysis
Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS <i>post hoc</i> analysis Open
Objective To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumo…
View article: ASAS recommendations on reporting axial spondyloarthritis clinical trials
ASAS recommendations on reporting axial spondyloarthritis clinical trials Open
These ASAS-endorsed recommendations on axSpA clinical trial reporting provide a standardised approach to reporting both baseline features as well as outcomes from axSpA clinical trials.
View article: Improving the delivery of multi-specialty care: the rise of the combined clinic service
Improving the delivery of multi-specialty care: the rise of the combined clinic service Open
View article: Late‐Onset Spondylarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A hitherto underappreciated entity where <scp>TNF</scp> or <scp>IL</scp>‐17 Blockade may have a Therapeutic Role
Late‐Onset Spondylarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A hitherto underappreciated entity where <span>TNF</span> or <span>IL</span>‐17 Blockade may have a Therapeutic Role Open
Background Polymyalgia rheumatica (PMR) is an age‐related inflammatory disease with shoulder‐hip girdle involvement. Magnetic resonance imaging (MRI) reveals extracapsular/entheseal soft tissue involvements in both PMR and spondyloarthriti…
View article: Multi-omic insights from a multi-ancestry genome-wide meta-analysis of ankylosing spondylitis reveal novel pathways of disease susceptibility
Multi-omic insights from a multi-ancestry genome-wide meta-analysis of ankylosing spondylitis reveal novel pathways of disease susceptibility Open
View article: Ixekizumab and Malignant Neoplasms
Ixekizumab and Malignant Neoplasms Open
Importance Assessing malignant neoplasm risk among patients with long-term biologic exposure is of interest. This study provides insight into the risk of malignant neoplasm among patients with psoriasis (PsO), psoriatic arthritis (PsA), or…
View article: Are investigator-initiated clinical trials becoming an ‘endangered species’?
Are investigator-initiated clinical trials becoming an ‘endangered species’? Open
View article: Effect of Nonsteroidal Anti‐Inflammatory Drugs on Sacroiliac Joint Inflammation, as Seen on Magnetic Resonance Imaging, in Axial Spondyloarthritis
Effect of Nonsteroidal Anti‐Inflammatory Drugs on Sacroiliac Joint Inflammation, as Seen on Magnetic Resonance Imaging, in Axial Spondyloarthritis Open
Objective Imaging evidence of active sacroiliitis is important for diagnosis, classification, and monitoring of axial spondyloarthritis (axSpA). However, there is no consistent guidance on whether patients should temporarily stop nonsteroi…
View article: POS1024 IMPACT OF PRIOR TUMOR NECROSIS FACTOR INHIBITOR TREATMENT AND BASELINE PSORIATIC ARTHRITIS DISEASE ACTIVITY ON MINIMAL CLINICALLY IMPORTANT IMPROVEMENT THRESHOLDS FOR EFFICACY OUTCOMES: POST HOC ANALYSIS OF THREE PHASE 3 STUDIES OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
POS1024 IMPACT OF PRIOR TUMOR NECROSIS FACTOR INHIBITOR TREATMENT AND BASELINE PSORIATIC ARTHRITIS DISEASE ACTIVITY ON MINIMAL CLINICALLY IMPORTANT IMPROVEMENT THRESHOLDS FOR EFFICACY OUTCOMES: POST HOC ANALYSIS OF THREE PHASE 3 STUDIES OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS Open
View article: POS0118 ASAS RECOMMENDATIONS ON REPORTING OUTCOMES OF CORE OUTCOME SET INSTRUMENTS IN AXIAL SPONDYLOARTHRITIS CLINICAL TRIALS
POS0118 ASAS RECOMMENDATIONS ON REPORTING OUTCOMES OF CORE OUTCOME SET INSTRUMENTS IN AXIAL SPONDYLOARTHRITIS CLINICAL TRIALS Open
View article: POS0126 TWO DISTINCT PATTERNS OF SACROILIAC JOINT BONE MARROW OEDEMA IN AXIAL SPONDYLOARTHRITIS ARE ASSOCIATED WITH HLA-B27 STATUS, BODY MASS INDEX AND/PSORIASIS
POS0126 TWO DISTINCT PATTERNS OF SACROILIAC JOINT BONE MARROW OEDEMA IN AXIAL SPONDYLOARTHRITIS ARE ASSOCIATED WITH HLA-B27 STATUS, BODY MASS INDEX AND/PSORIASIS Open
View article: ABS0273 NEW PATHOGENIC PATHWAYS IN ANKYLOSING SPONDYLITIS IDENTIFIED THROUGH MULTI-ANCESTRY GENOMEWIDE ASSOCIATION STUDY
ABS0273 NEW PATHOGENIC PATHWAYS IN ANKYLOSING SPONDYLITIS IDENTIFIED THROUGH MULTI-ANCESTRY GENOMEWIDE ASSOCIATION STUDY Open
View article: POS1269 EULAR POINTS TO CONSIDER FOR THE DEFINITIONS OF DIFFICULT-TO-MANAGE AND TREATMENT-REFRACTORY PSORIATIC ARTHRITIS
POS1269 EULAR POINTS TO CONSIDER FOR THE DEFINITIONS OF DIFFICULT-TO-MANAGE AND TREATMENT-REFRACTORY PSORIATIC ARTHRITIS Open
View article: POS0921 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PAIN, MORNING STIFFNESS, FATIGUE, PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES
POS0921 SUSTAINED IMPROVEMENTS WITH BIMEKIZUMAB IN PAIN, MORNING STIFFNESS, FATIGUE, PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 3-YEAR RESULTS FROM TWO PHASE 3 STUDIES Open
View article: POS0755 EXPLORING THE DIFFERENTIAL EFFECTS OF HLA-B27 AND BIOLOGICAL SEX ON CLINICAL CHARACTERISTICS, INFLAMMATORY BURDEN, AND SERVICE UTILISATION IN axSpA TO IMPROVE SERVICE DELIVERY AND REDUCE DELAY TO DIAGNOSIS IN axSpA
POS0755 EXPLORING THE DIFFERENTIAL EFFECTS OF HLA-B27 AND BIOLOGICAL SEX ON CLINICAL CHARACTERISTICS, INFLAMMATORY BURDEN, AND SERVICE UTILISATION IN axSpA TO IMPROVE SERVICE DELIVERY AND REDUCE DELAY TO DIAGNOSIS IN axSpA Open
View article: Isotretinoin-associated cervical osteophytosis – Authors' reply
Isotretinoin-associated cervical osteophytosis – Authors' reply Open
View article: Impact of Working From Home on the Psychological Well‐Being of 365 European Patients With Rheumatic Diseases During COVID‐19 Pandemic. Results of the REUMAVID Study
Impact of Working From Home on the Psychological Well‐Being of 365 European Patients With Rheumatic Diseases During COVID‐19 Pandemic. Results of the REUMAVID Study Open
Objective To evaluate the impact of home working on the psychological well‐being of European patients with Rheumatic and Musculoskeletal Diseases (RMDs) during the COVID‐19 pandemic. Methods REUMAVID is a cross‐sectional study that collect…
View article: How Should We Count the Toe Joints in the 66/68 Joint Count in Psoriatic Arthritis? Results of an International Survey
How Should We Count the Toe Joints in the 66/68 Joint Count in Psoriatic Arthritis? Results of an International Survey Open
View article: The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects
The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects Open
View article: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs Open
CC BY‑NC‑ND 4.0 (open access)
View article: Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs Open
Background and rationale for guideline development: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly affects the spine and sacroiliac joints [1]. It can also involve peripheral joints and entheses, and…
View article: P179 Bimekizumab demonstrates sustained improvement in quality of life up to week 104 in patients across the full spectrum of axial spondyloarthritis: results from phase 3 studies
P179 Bimekizumab demonstrates sustained improvement in quality of life up to week 104 in patients across the full spectrum of axial spondyloarthritis: results from phase 3 studies Open
Background/Aims Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A and has demonstrated rapid and clinically meaningful improvements in disease activity in patients across the full spectr…
View article: E093 Sustained improvement in clinical outcomes and long-term safety of bimekizumab in patients across the spectrum of axial spondyloarthritis up to week 104: results from two phase 3 studies
E093 Sustained improvement in clinical outcomes and long-term safety of bimekizumab in patients across the spectrum of axial spondyloarthritis up to week 104: results from two phase 3 studies Open
Background/Aims Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A and has shown rapid, clinically meaningful improvements in disease activity across the axial spondyloarthritis (axSpA) s…